Dr. Reddy’s launches first-to-market generic Bosutinib 400mg in U.S. oncology market
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.
On June 13, 2026, Dr. Reddy’s Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, expanding its oncology portfolio and international footprint. Developed and manufactured by MSN Laboratories, with Dr. Reddy’s holding exclusive U.S. marketing rights and 180 days of generic exclusivity for this strength, the product targets a Bosulif brand market worth about $253.8 million in U.S. sales over the 12 months to April 2026, underscoring the company’s push into high-value complex oncology generics and improved patient access to lower-cost therapies.
Executives from Dr. Reddy’s and MSN highlighted that the launch showcases timely entry into priority therapies, strengthens their oncology offerings and demonstrates MSN’s capabilities in complex oncology development and manufacturing. For stakeholders, the move positions Dr. Reddy’s to capture significant early share in a sizeable U.S. oncology segment, reinforces its role as a partner in affordable cancer care, and exemplifies how strategic collaborations can enhance competitiveness in the global generics market.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock,
click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984 and focused on providing affordable and innovative medicines. Its portfolio spans APIs, generics, branded generics, biosimilars and OTC products, with key therapeutic areas including oncology, gastrointestinal, cardiovascular, diabetology, pain management and dermatology, and major markets in the U.S., India, Russia & CIS, China, Brazil and Europe.
Average Trading Volume: 2,406,146
Technical Sentiment Signal: Buy
Current Market Cap: $11.23B
Learn more about RDY stock on TipRanks’ Stock Analysis page.
